Form 4: Rhythm Pharmaceuticals CFO Exercises Stock Options, Increases Common Stock Holdings
Insider Transaction Report
Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, exercised stock options to acquire 6,986 shares of common stock at an exercise price of $6.88 per share.
Summary
- Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), executed a transaction on July 7, 2025.
- The transaction involved the exercise of 6,986 stock options at an exercise price of $6.88 per share.
- As a result of this exercise, 6,986 shares of common stock were acquired.
- Following this transaction, Hunter C. Smith directly beneficially owns 116,915 shares of common stock.
- The exercised stock option was fully vested.
- Hunter C. Smith now directly beneficially owns 70,208 derivative securities (stock options) after the transaction.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive as an insider exercising options can be interpreted as a sign of confidence in the company's future, especially when the options are fully vested.
Positives
- The exercise of stock options by a Chief Financial Officer can signal confidence in the company's future performance, especially if the current market price is above the exercise price.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It is a routine disclosure of a corporate officer's equity activity.
Related Party Transactions
- The transaction involves an insider (Chief Financial Officer Hunter C. Smith) acquiring company stock through the exercise of stock options, which is a common form of related party transaction in the context of executive compensation.
Stakeholder Impact
- Shareholders: The transaction indicates an increase in direct ownership by a key executive, which may be viewed positively as alignment of interests.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 07/07/2025 | Date of transaction (exercise of stock options and acquisition of common stock). |
| 07/08/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
| 08/08/2027 | Expiration date of the exercised stock options. |
Keywords
Rhythm Pharmaceuticals, RYTM, Hunter C. Smith, Chief Financial Officer, SEC Form 4, Insider Trading, Stock Options, Equity Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.